me-1

Malic enzyme inhibitor ME1 (ME1) is a specific inhibitor of Malic enzyme (IC50 = 0.15 μM). Malic enzyme inhibitor ME1 reduces cell viability/metabolic activity.

(S,R,S)-AHPC-Me-10-bromodecanoic acid is an E3 ligase ligand-linker conjugate composed of VHL ligand 2 and the linker 10-bromoheptanoic acid. This compound can be utilized in the synthesis of PROTACPI3Kδ degrader-1.

(S,R,S)-AHPC-Me-12-((4-Bromobutyl)amino)dodecanamide comprises a VHL ligand for recruiting E3 ubiquitin ligases and a PROTAC linker. This compound is used in synthesizing PROTACs such as MS934. MS934 represents a novel and improved VHL-recruiting MEK1/2 PROTAC degrader.

ME-143, a second-generation tumor-specific NADH oxidase inhibitor, exhibits efficacy by inhibiting the WNT/β-catenin pathway in colorectal cancer cells. Demonstrating broad activity against cancers both in vitro and in vivo, this compound presents a promising therapeutic avenue.

MC-GGFG-AM-(10Me-11F-Camptothecin) serves as a linker-payload conjugate in the synthesis of ZW251, an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 comprises a humanized IgG1 antibody linked to ZD06519, a novel camptothecin-based topoisomerase 1 inhibitor, through a maleimide-anchor and a cleavable glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) linker. ZW251 demonstrates strong affinity for GPC3 in both human and cynomolgus monkey cells, characterized by rapid internalization in GPC3-positive Hepatocellular Carcinoma (HCC) cell lines and induces bystander-mediated killing of GPC3-negative cancer cells [1].

7-Hydroxyethyl carbamate-(10Me-11F-Camptothecin) is an analogue of Camptothecin and serves as an ADC cytotoxin. It is utilized in the synthesis of ADCs and for cancer research [1].

MC-GGFG-AM-(10Me-11F-Camptothecin) intermediate-1 (compound 19-2) serves as a synthetic intermediary for the creation of the drug-linker conjugate, MC-GGFG-AM-(10Me-11F-Camptothecin), utilized in the synthesis of ADCs (Antibody-Drug Conjugates). This intermediate allows for the incorporation of functional groups.

SAMe-1,4-Butanedisulfonate, a naturally occurring compound, serves as a methyl donor in the central nervous system. It exhibits antidepressant activity and may be utilized for research into central nervous system disorders.

AI-10-47 (1H-Benzimidazole, 2-(2-pyridinyl)-6-(trifluoromethoxy)-AI-10-47) is a small molecule inhibitor of CBFβ-RUNX binding(IC50 : 3.2 μM).

GSK2850163 is a novel inhibitor of inositol-requiring enzyme-1 alpha (IRE1α), effectively inhibiting both its RNase activity and IRE1α kinase activity (IC50s: 200 and 20 nM).

Sunitinib Malate (Sunitinib) is an indolinone-based tyrosine kinase inhibitor. It blocks the tyrosine kinase activities of VEGFR2, PDGFRβ (IC50: 80/2 nM), and c-kit.

Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that inhibits VEGFR2 and PDGFRβ (IC50=80/2 nM). It exhibits antitumor activity and is used for treating kidney cancer and gastrointestinal tumors.

L-Ornithine ((S)-2, 5-diaminopentanoic acid) is a non-protein amino acid. L-Ornithine is mainly used in the urea cycle to remove excess nitrogen from the body. L-Ornithine is renoprotective. L-Ornithine has antifatigue effects.

Cefditoren pivoxil (ME 1207) is a semi-synthetic, broad-spectrum, beta-lactamase resistant, third-generation cephalosporin antibiotic with bactericidal activity.

Genistein (NPI 031L) is a naturally occurring soy isoflavone, a multi-targeted tyrosine kinase inhibitor. Genistein has antitumor, antioxidant, and anthelmintic properties, and also produces estrogen-like effects in the body.

6-Bromo-2-hydroxy-3-methoxybenzaldehyde (NSC-95682) is an inhibitor of IRE-1α with an IC50 value of 0.08 μM.

Cefditoren Pivoxil is an orally active antibiotic with broad-spectrum antibacterial properties, and Cefditoren demonstrates potent inhibition against both Gram-negative and Gram-positive bacterial pathogens. Cefditoren exhibits a MIC50 of 0.25–0.5 mg/L against Streptococcus pneumoniae, Cefditoren is widely used for treating respiratory tract infections and skin infections. Cefditoren remains valuable in antimicrobial therapy owing to its favorable pharmacokinetic characteristics and reliable therapeutic efficacy.

Kira8 (AMG-18) is a mono-selective IRE1α inhibitor that allosterically attenuates IRE1α RNase activity with an IC50 of 5.9 nM.

MKC9989 is an inhibitor of Hydroxy aryl aldehydes (HAA). MKC9989 also inhibits IRE1α with an IC50 of 0.23 to 44 μM.

Cefditoren sodium is a cephalosporin antibiotic potentially for the treatment of bacterial infection. The expression levels of Mrp2, Bcrp, Oat2 mRNA were markedly increased, while P-gp and Oct1 mRNA were decreased. In concordance with RT-PCR results, Mrp2

ABL127 is a selective and covalent inhibitor of protein methylesterase 1 (PME-1), with IC50 values of 6.4 nM and 4.2 nM in HEK293T and MDA-MB-231 cells, respectively.

MKC8866 is a selective IRE1 RNase inhibitor (IC50: 0.29 μM in human vitro). MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibit prostate cancer (PCa) tumor growth.

ME1111, a succinate dehydrogenase inhibitor of Trichophyton species, serves as an antifungal agent effective against dermatophytes. Notably proficient in penetrating human nails, it is utilized in onychomycosis research.

Toyocamycin (Vengicide) is an adenosine analog produced by Actinomycetes, functioning as an XBP1 inhibitor and inhibiting IRE1α-induced ATP-dependent XBP1 mRNA cleavage (IC50: 80 nM), and induces apoptosis.